

## **iJOBS Simulation: Research Equity 092519**

Prior to the event, you should look at these slides that were presented by Blueprint Medicines at the 2018 Connective Tissue Oncology Society Annual Meeting).

<https://www.blueprintmedicines.com/wp-content/uploads/2019/01/CTOS-Avapritinib-Update-Nov-2018.pdf>

If you want, you can also look at these two items but they are option

1.) poster presented by Blueprint at 2019 American Society of Clinical Oncology Annual Meeting (<https://www.blueprintmedicines.com/wp-content/uploads/2019/06/Blueprint-Medicines-ASCO-2019-Avapritinib-GIST-Poster.pdf>), and

2.) Blueprint Medicines' website where they highlight their pipeline (<https://www.blueprintmedicines.com/pipeline/>)

At time of the exercise, participants should be provided these two press releases sent out by Deciphera Pharmaceuticals (<https://investors.deciphera.com/news-releases/news-release-details/deciphera-pharmaceuticals-announces-positive-top-line-results>

and (<https://investors.deciphera.com/news-releases/news-release-details/deciphera-pharmaceuticals-reports-positive-updated-phase-1-data>) and given a limited amount of time (i.e. ~30 minutes) to write up a one-pager.

Please bring your laptop for the activity we will do during the session and write a one page document as a team of 3 people.

1. What happened?
2. What does the new data from Aug 13 look like?
3. How does it compared to the previous competitor data?
4. What are the potential implications on both of these drugs, assuming both become commercialized?